Search results for "Elea"

showing 10 items of 772 documents

Concomitant gonadotropin-releasing hormone agonist and menotropin treatment for the synchronized induction of multiple follicles.

1988

In an effort to overcome possible interference by endogenous gonadotropin-ovarian hormone dynamics, desensitization of the pituitary gonadotropins by a gonadotropin-releasing hormone agonist (GnRHa) was achieved in 12 women with repeatedly failed attempts at multiple follicular stimulation. Eight women were scheduled for in vitro fertilization (IVF) and embryo transfer (ET), and 4 for gamete intrafallopian transfer (GIFT). Stimulation failure was characterized by premature luteinization, poor estradiol (E2) response, or inadequate follicular growth. The agonist was administered by nasal spray 500 to 600 micrograms/day beginning on days 21 to 23 of the menstrual cycle. A rapid desensitizatio…

AgonistAdultendocrine systemmedicine.medical_specialtyMenotropinsmedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilization in VitroBiologyBuserelinReproductive TechniquesOvulation InductionInternal medicineGonadotropin-releasing hormone agonistFollicular phasemedicineHumansGamete intrafallopian transferMenstrual cyclemedia_commonIn vitro fertilisationObstetrics and GynecologyEmbryo TransferEmbryo transferEndocrinologyReproductive MedicineFemaleMenotropinhormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist…

2005

Background This descriptive study evaluates the impact on endometrial development of standard and high doses of a GnRH antagonist in stimulated cycles compared with GnRH agonist and natural cycles. Methods Thirty-one oocyte donors were treated with a combination of rFSH and 0.25 mg/day ganirelix (standard dose), 2 mg/day ganirelix (high dose) or 0.6 mg/day buserelin (long protocol). Vaginal progesterone (200 mg/day) was administered in the luteal phase. Endometrial biopsies were performed 2 and 7 days after HCG administration. Additional biopsies were carried out in a subset of 12 subjects, 2 and 7 days following the LH peak of their previous natural cycle. Biopsies were evaluated histologi…

AgonistAdultendocrine systemmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentFertilization in VitroLuteal phaseBiologyLuteal PhaseEndometriumBuserelinChorionic GonadotropinGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneEndometriumOvulation InductionInternal medicinemedicineHumansUltrasonicsGanirelixOligonucleotide Array Sequence Analysismedicine.diagnostic_testOocyte DonationRehabilitationObstetrics and GynecologyBuserelinmedicine.anatomical_structureEndocrinologyReproductive MedicineGene Expression RegulationReceptors EstrogenMicroscopy Electron ScanningOocytesRNAOvulation inductionFemaleFollicle Stimulating HormoneReceptors Progesteronehormones hormone substitutes and hormone antagonistsmedicine.drugEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

The role of gonadotropin-releasing hormone in murine preimplantation embryonic development.

1999

Previous studies have established the presence of an extrahypothalamic GnRH in a variety of tissues. GnRH receptor is known to be present in the placenta, which produces and secretes the decapeptide from the very early stages of placentation. We hypothesized that GnRH may play a role in the preimplantation development of embryos. To examine this hypothesis, we assessed GnRH and GnRH receptor messenger RNA (mRNA; RT-PCR) and protein expression (Immunohistochemistry) in preimplantation murine embryos at various developmental stages. Furthermore, preimplantation murine embryos were cultured with GnRH agonist and antagonist in vitro to assess the influence of GnRH analogs on embryo development.…

Agonistendocrine systemmedicine.medical_specialtyanimal structuresTranscription Geneticmedicine.drug_classZygoteMice Inbred StrainsGonadotropin-releasing hormoneBiologyMorulaGonadotropin-Releasing HormoneEmbryonic and Fetal DevelopmentMiceEndocrinologyInternal medicinePlacentamedicineAnimalsBlastocystRNA MessengerMessenger RNAReverse Transcriptase Polymerase Chain ReactionEmbryogenesisPlacentationGene Expression Regulation DevelopmentalEmbryoEndocrinologymedicine.anatomical_structureBlastocystembryonic structureshormones hormone substitutes and hormone antagonistsReceptors LHRHEndocrinology
researchProduct

Aroma release in the oral cavity after wine intake is influenced by wine matrix composition

2018

The aim of this study has been to investigate if wine matrix composition might influence the interaction between odorants and oral mucosa in the oral cavity during a “wine intake-like” situation. Aroma released after exposing the oral cavity of three individuals to different wines (n = 12) previously spiked with six target aromas was followed by an -in vivo intra-oral SPME approach. Results showed a significant effect of wine matrix composition on the intra-oral aroma release of certain odorants. Among the wine matrix parameters, phenolic compounds showed the largest impact. This effect was dependent on their chemical structure. Some phenolic acids (e.g. hippuric, caffeic) were associated t…

Alcohol DrinkingAroma-wine matrix interactions[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionIntra-oral aroma releasephenolic metabolitessalivary proteinsWineperceptionGas Chromatography-Mass SpectrometryAnalytical ChemistrytanninMatrix (chemical analysis)chemistry.chemical_compound0404 agricultural biotechnologyPhenolic compositionLinaloolmodel wineHumansFood scienceAromaWineMouthChromatographybiologyretronasal aromaEthyl hexanoatefood and beverages04 agricultural and veterinary sciencesGeneral Medicinered wineWine faultbiology.organism_classificationhuman feces040401 food sciencestomatognathic diseaseschemistryWineIntra-oral aroma releaseOdorantsmolecular-levelComposition (visual arts)Oral mucosaGas chromatography–mass spectrometryheadspace[SDV.AEN]Life Sciences [q-bio]/Food and NutritionFood ScienceAroma persistence
researchProduct

Selective adsorption of oppositely charged PNIPAAM on halloysite surfaces: a route to thermo-responsive nanocarriers.

2018

Halloysite nanotubes were functionalized with stimuli-responsive macromolecules to generate smart nanohybrids. Poly(N-isopropylacrylamide)-co-methacrylic acid (PNIPAAM-co-MA) was selectively adsorbed into halloysite lumen by exploiting electrostatic interactions. Amine-terminated PNIPAAM polymer was also investigated that selectively interacts with the outer surface of the nanotubes. The adsorption site has a profound effect on the thermodynamic behavior and therefore temperature responsive features of the hybrid material. The drug release kinetics was investigated by using diclofenac as a non-steroidal anti-inflammatory drug model. The release kinetics depends on the nanoarchitecture of th…

AmideMaterials scienceTechnological applicationBioengineering02 engineering and technologyengineering.material010402 general chemistry01 natural sciencesHalloysiteLower critical solution temperatureAcrylic monomerchemistry.chemical_compoundAdsorptionthermo-responsive materialKaoliniteGeneral Materials ScienceElectrical and Electronic EngineeringNon-steroidal anti-inflammatory drugPoly (n isopropylacrylamide)Hybrid materialTargeted drug deliveryThermodynamic behaviors Controlled drug deliveryMechanical EngineeringHalloysiteGeneral Chemistry021001 nanoscience & nanotechnologyControlled release0104 chemical sciencesNanotubeHydrogelChemical engineeringchemistryMechanics of MaterialsSelective adsorptionSelf-healing hydrogelsengineeringPoly(N-isopropylacrylamide)0210 nano-technologyHybrid materialTemperature-responsivecontrolled releaseYarn Controlled releaseThermo-responsiveNanotechnology
researchProduct

Relationship between particle size and dissolution rate of bulk powders and sieving characterized fractions of two qualities of orthoboric acid

1996

Drug Dev. Ind. Pharm. ISI Document Delivery No.: VN279 Times Cited: 1 Cited Reference Count: 22 Tromelin, A Habillon, S Andres, C Pourcelot, Y Chaillot, B; International audience; We have carried out a study of the particle size distribution and aqueous dissolution rate of two commercially available qualities of orthoboric acid, labeled ''crystal'' (ABC) and ''powder'' (ABP). In a previous work, we have shown that the two commercial qualities of orthoboric acid chosen as model compound (''powder'' and ''crystal'') are related to the same crystal network in spite of their different names. However, these two qualities have very different size particle distributions, as previously determined b…

Analytical chemistryPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacyrelease03 medical and health sciences0302 clinical medicine[CHIM.ANAL]Chemical Sciences/Analytical chemistryDrug DiscoverymorphologySize fractionsDissolution testingdissolution rateDissolutionfractal geometryPharmacologyAqueous solutionChemistryOrganic Chemistryparticle size021001 nanoscience & nanotechnologyLaser light scattering[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistryCrystallography[SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacologyParticle-size distributionParticle size0210 nano-technology
researchProduct

Platone e gli Eleati (I)

2017

Si argomenta (alla luce del "Sofista") come nel "Parmenide" Platone cerchi di mostrare a quali contraddizioni e assurdità porti la dialettica sull´essere di Parmenide. Se da un lato Platone rileva in maniera impietosa i limiti della dialettica eleatica, dall´altro sembra riconoscere a Parmenide alcuni meriti.

Ancient Philosophy Plato Parmenides Eleatics
researchProduct

Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation.

1973

Dextran sulfate (DS) consumed C3 in C4 deficient guinea pig serum. This temperature-dependent reaction required Mg++ ions and could therefore be blocked by EDTA. Isolated C3 was not influenced by DS, but serum factors were required for C3 consumption. The C3 proactivator as well as C3 were converted to their activated state by DS in guinea pig and human serum, as revealed by immunoelectrophoretical analysis. DS generated anaphylatoxin activity in serum. It is concluded that DS activates C3 via the alternate pathway of complement activation. This potency of the polyanion might serve as a tentative explanation for its T cell-replacing effect in an antibody-forming system, which was reported b…

AnionsAlternate pathwayT cellT-LymphocytesImmunologyBiologyHistamine ReleaseC3 proactivatorGuinea pigIleummedicineImmunology and AllergyPotencyHumansAnaphylatoxinAnaphylaxisImmunoelectrophoresisToxins BiologicalImmune SeraDextransComplement System ProteinsComplement systemKineticsmedicine.anatomical_structureDextran sulfateBiochemistryEuropean journal of immunology
researchProduct

Carbon Monoxide-Releasing Molecules: A Pharmacological Expedient to Counteract Inflammation

2008

Carbon monoxide (CO) mediates many of the biological effects that are attributed to heme oxygenase (HO), the enzyme responsible for CO production in mammals. Antioxidant and anti-inflammatory activities of HO-1, the inducible isoform of heme oxygenase, have been demonstrated in a variety of disease models and a therapeutic exploitation of this pathway is currently under scrutiny. In this context, the liberation of CO from CO-releasing molecules (CO-RMs) is extremely attractive as these compounds may form the basis of a new class of pharmaceuticals. Recent investigations indicate that HO-1 and CO modulate important processes in chronic inflammation; these include the control of immune respon…

Anti-Inflammatory AgentsContext (language use)InflammationOsteoarthritisPharmacologyRutheniumArthritis RheumatoidDegenerative diseaseImmune systemOsteoarthritisDrug DiscoveryOrganometallic CompoundsAnimalsHumansMedicineInflammationPharmacologyCarbon Monoxidebusiness.industrymedicine.diseaseCarbon monoxide-releasing moleculesHeme oxygenaseOxidative StressImmunologyMetalloproteasesCytokinesmedicine.symptomSignal transductionbusinessHeme Oxygenase-1Signal TransductionCurrent Pharmaceutical Design
researchProduct